RPT193

DRUG4 trials

Sponsors

Rapt Therapeutics Inc., RAPT Therapeutics, Inc.

Conditions

AsthmaAtopic Dermatitis

Phase 1

A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis

CompletedNCT04271514

RAPT Therapeutics, Inc.Atopic Dermatitis

Start: 2019-08-12End: 2021-04-26Updated: 2021-09-30

Phase 2

An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

TerminatedNCT05399368

RAPT Therapeutics, Inc.Atopic Dermatitis

Start: 2022-06-07End: 2024-05-24Updated: 2026-03-23

Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma

TerminatedNCT05935332

RAPT Therapeutics, Inc.Asthma

Start: 2023-07-05End: 2024-06-21Updated: 2026-03-23

A Phase 2 study to evaluate the efficacy and safety of RPT193 in adults with moderate-to-severe T2-high asthma who are partially controlled on inhaled corticosteroid and long-acting beta 2 agonist therapy

CompletedCTIS2022-502854-16-00

Rapt Therapeutics Inc.Asthma

Start: 2023-11-26End: 2024-06-21Target: 71Updated: 2024-02-21

Related Papers

Clinical and molecular effects of oral <scp>CCR4</scp> antagonist <scp>RPT193</scp> in atopic dermatitis: A Phase 1 study

Allergy2023-11-2023 citations